13 hrs ago | Freshnews
Edwards Lifesciences to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference
Thomas M. Abate, Edwards Lifesciences' corporate vice president, chief financial officer, is scheduled to speak to conference attendees at 2:40 p.m. PDT.
Canaccord Genuity Reiterates "Buy" Rating on Edwards Lifesciences
A number of other firms have also recently commented on EW. Analysts at Goldman Sachs raised their price target on shares of Edwards Lifesciences from $90.00 to $97.00 in a research note to investors on Wednesday, May 2nd.
Market Report, "Edwards Lifesciences Corporation - SWOT Analysis", published
Edwards Lifesciences Corporation - SWOT Analysis company profile is the essential source for top-level company data and information.
Edwards Lifesciences' CEO Hosts Annual Meeting of Stockholders Conference
Welcome, good morning everyone. This is the 2012 Annual Meeting of Stockholders for Edwards Lifesciences.
Equity Insights May 7th: Warner Chilcott, Global Payments, Edwards Lifesciences, NetApp, Solazyme
Warner Chilcott plc : BofA/Merrill is assuming assuming a sale of Warner Chilcott and said if it does not happen there are other alternatives to drive shares higher.
Hearts are key to J&J strategy
If you are interested in this story, you might be interested in others from The Journal Gazette.
Edwards Lifesciences to Webcast Annual Meeting of Stockholders
A live webcast of the meeting will be available to all interested parties on the Edwards Lifesciences' investor relations website at http://www.edwards.com/InvestorRelations/Pages/EventCalendar.aspx . A replay of the webcast can be accessed at this site approximately one hour after the conclusion of the live event and will be available for 30 days ... (more)
New Data on Edwards Intuity Valve System Demonstrate Promise of Rapid Deployment Platform
Edwards Lifesciences Corporation , the global leader in the science of heart valves and hemodynamic monitoring, announced that new data from the European multi-center TRITON trial studying the EDWARDS INTUITY valve system highlights the promise of several important benefits, including the facilitation of small-incision surgery for aortic valve ... (more)
Edwards Lifesciences Price Target Raised to $97.00 at Goldman Sachs
The firm currently has a "buy" rating on the stock. The analysts wrote, "Now that the guidelines have been issued, we think the ramp in center opening should accelerate .
Edwards Lifesciences ([[EW]] +0.9%) shrugs off this mornings...
Edwards Lifesciences shrugs off this mornings weakness after the Centers for Medicare & Medical Services announced it will cover Transcatheter Aortic Valve Replacement procedures for the treatment of symptomatic aortic valve stenosis, for which EW 's Sapien is a marquee product.